Origin of threshold behaviour in psoriatic skin

Dermatology

Volumn 217, Issue 4, 2008, Pages 295-298

  Lejeune, O ^a,c   Simonart, T ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Hysteresis; Immunocytes, feedback; Keratinocytes, feedback; Psoriasis, critical phenomenon

Indexed keywords

CXCL1 CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CYTOKINE PRODUCTION; EPIDERMIS HYPERPLASIA; HOMEOSTASIS; HUMAN; KERATINOCYTE; LYMPHOCYTE; NEGATIVE FEEDBACK; POSITIVE FEEDBACK; PRIORITY JOURNAL; PSORIASIS; SKIN INFLAMMATION;

EPIDERMIS; FEEDBACK, BIOCHEMICAL; HOMEOSTASIS; HUMANS; KERATINOCYTES; PSORIASIS; T-LYMPHOCYTES;

EID: 49249138813     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151354     Document Type: Article

References (60)

1. Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, van de Kerkhof PC, Traupe H, de Jongh G, den Heijer M, Reis A, Armour JA, Schalkwijk J: Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008;40:23-25.
2. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, Schreiber S, Kabelitz D, Lim HW, Voorhees JJ, Christophers E, Elder JT, Weichenthal M: Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008;128:1653-1661.
3. Heenen M, Galand P, de Maertelaer V, Heenen PH: Psoriasis: hyperproliferation cannot induce characteristic epidermal morphology. Cell Tissue Kinet 1987;20:561-570.
4. Iizuka H, Honda H, Ishida-Yamamoto A: Epidermal remodeling in psoriasis. II. A quantitative analysis of the epidermal architecture. J Invest Dermatol 1997;109:806-810.
5. Franssen ME, Zeeuwen PL, Vierwinden G, van de Kerkhof PC, Schalkwijk J, van Erp PE: Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis. J Invest Dermatol 2005;124:373-383.
6. Guilhou JJ: Immunopathogenesis of psoriasis: news in an old concept. Dermatology 1998;197:310-312.
7. Schon MP, Boehncke WH: Psoriasis. N Engl J Med 2005;352:1899-1912.
8. Krueger G, Ellis CN: Psoriasis - recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005;53:S94-S100.
9. Lowes MA, Bowcock AM, Krueger JG: Pathogenesis and therapy of psoriasis. Nature 2007;445:866-873.
10. Griffiths CE, Barker JN: Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-271.
11. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, Senices M, Gill D, Dunussi-Joannopoulos K, Collins M, Nickerson-Nutter C, Fouser LA, Young DA: IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008;118:597-607.
12. Hobbs RM, Silva-Vargas V, Groves R, Watt FM: Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J Invest Dermatol 2004;123:503-515.
13. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, Itami S, Nickoloff BJ, Di Giovanni J: Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005;11:43-49.
14. Voskas D, Jones N, Van Slyke P, Sturk C, Chang W, Haninec A, Babichev YO, Tran J, Master Z, Chen S, Ward N, et al: A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol 2005;166:843-855.
15. Heenen M, Simonart T: Biological agents and psoriatic epidermis: what are we ultimately targeting? Dermatology 2006;212:321-323.
16. Nickoloff BJ: Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 2006;12:102-106.
17. Simonart T, Heenen M: T cell/keratinocyte interactions in psoriasis: where is the trigger? Br J Dermatol 2007;156:171-172.
18. van de Kerkhof PC: The evolution of the psoriatic lesion. Br J Dermatol 2007;157:4-15.
19. Kalayciyan A, Aydemir EH, Kotogyan A: Experimental Koebner phenomenon in patients with psoriasis. Dermatology 2007;215:114-117.
20. Körver JE, van Duijnhoven MW, Pasch MC, van Erp PE, van de Kerkhof PC: Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis. Br J Dermatol 2006;155:688-694.
21. Hennings H, Elgjo K: Epidermal regeneration after cellophane tape stripping of hairless mouse skin. Cell Tissue Kinet 1970;3:243-252.
22. Fisher LB, Maibach HI: Physical occlusion controlling epidermal mitosis. J Invest Dermatol 1972;59:106-108.
23. Gottlieb AB, Staiano-Coico L, Cohen SR, Varghese M, Carter DM: Occlusive hydrocolloid dressings decrease keratinocyte population growth fraction and clinical scale and skin thickness in active psoriatic plaques. J Dermatol Sci 1990;1:93-96.
24. Leigh IM, Navsaria H, Purkis PE, McKay IA, Bowden PE, Riddle PN: Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol 1995;133:501-511.
25. Nicolis G, Prigogine I: Self-Organisation in Nonequilibrium Systems. New York, Wiley, 1997.
26. Keener J, Sneyd J: Mathematical Physiology. New York, Springer, 1998.
27. Murray JD: Mathematical Biology. I. An Introduction. New York, Springer, 2002. 28 Lefever R, Lejeune O: Dynamical aspects of immune anti-tumor cytotoxic reactions; in Greppin H, Bronzon M, Degli Agosti R (eds): Some Physicochemical and Mathematical Tools for Understanding of the Living Systems. Geneva, University of Geneva, 1993, pp 169-191.
28. Lejeune O, Chaplain MAJ, El Akili I: Oscillations and bistability in the dynamics of cytotoxic reactions mediated by the response of immune cells to solid tumours. Math Comput Model 2008;47:649-662.
29. Goldbeter A: Biochemical Oscillations and Cellular Rhythms. Cambridge, Cambridge University Press, 1996.
30. Laptev MV, Nikulin NK: Synchronization of oscillations of proliferation of keratinocytes in psoriatic skin by external periodic force: a mathematical model. J Theor Biol 2005;235:485-494.
31. Takematsu H, Tagami H: Granulocyte-macrophage colony-stimulating factor in psoriasis. Dermatologica 1990;181:16-20. 33 Tettelbach W, Nanney L, Ellis D, King L, Richmond A: Localization of MGSA/GRO protein in cutaneous lesions. J Cutan Pathol 1993;20:259-266.
32. Won YH, Sauder DN, McKenzie RC: Cyclosporin A inhibits keratinocyte cytokine gene expression. Br J Dermatol 1994;130:312-319.
33. Nickoloff BJ: The immunologic and genetic basis of psoriasis. Arch Dermatol 1999;135:1104-1110.
34. Gillitzer R, Ritter U, Spandau U, Goebeler M, Brocker EB: Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 1996;107:778-782.
35. Kulke R, Todt-Pingel I, Rademacher D, Rowert J, Schroder JM, Christophers E: Co-localized overexpression of GRO-alpha and IL-8 mRNA is restricted to the suprapapillary layers of psoriatic lesions. J Invest Dermatol 1996;106:526-530.
36. Steude J, Kulke R, Christophers E: Interleukin-1-stimulated secretion of interleukin-8 and growth-related oncogene-alpha demonstrates greatly enhanced keratinocyte growth in human raft cultured epidermis. J Invest Dermatol 2002;119:1254-1260.
37. Schmid P, Cox D, McMaster GK, Itin P: In situ hybridization analysis of cytokine, protooncogene and tumour suppressor gene expression in psoriasis. Arch Dermatol Res 1993;285:334-340.
38. Prens EP, Benne K, van Damme J, Bakkus M, Brakel K, Benner R, van Joost T: Interleukin-1 and interleukin-6 in psoriasis. J Invest Dermatol 1990;95:121S-124S.
39. Castells-Rodellas A, Castell JV, Ramirez-Bosca A, Nicolas JF, Valcuende-Cavero F, Thivolet J: Interleukin-6 in normal skin and psoriasis. Acta Derm Venereol 1992;72:165-168.
40. Ohta Y, Nishiyama S, Nishioka K: In situ expression of interleukin-6 in psoriatic epidermis during treatment. J Dermatol 1994;21:301-307.
41. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD: Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-649.
42. Funding AT, Johansen C, Kragballe K, Otkjaer K, Jensen UB, Madsen MW, Fjording MS, Finnemann J, Skak-Nielsen T, Paludan SR, Iversen L: Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. J Invest Dermatol 2006;126:1784-1791.
43. Ozawa M, Terui T, Tagami H: Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. Dermatology 2005;211:249-255.
44. Gesser B, Johansen C, Rasmussen MK, Funding AT, Otkjaer K, Kjellerup RB, Kragballe K, Iversen L: Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. J Invest Dermatol 2007;127:2129-2137.
45. Dal Pra I, Chiarini A, Pacchiana R, Zumiani G, Zanoni M, Armato U: Comano's (Trentino) thermal water interferes with tumour necrosis factor-alpha expression and interleukin-8 production and secretion by cultured human psoriatic keratinocytes: yet other mechanisms of its anti-psoriatic action. Int J Mol Med 2007;19:373-379.
46. Ruckert R, Asadullah K, Seifert M, Budagian VM, Arnold R, Trombotto C, Paus R, Bulfone-Paus S: Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol 2000;165:2240-2250.
47. Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P, Lebecque S: Interleukin-17. Int Rev Immunol 1998;16:541-551.
48. Li HH, Lin YC, Chen PJ, Hsiao CH, Lee JY, Chen WC, Tzung TY, Wu JC, Chang MS: Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol 2005;153:591-595.
49. Romer J, Hasselager E, Norby PL, Steiniche T, Thorn Clausen J, Kragballe K: Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol 2003;121:1306-1311.
50. Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, Sterry W, Asadullah K, Sabat R: Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006;15:991-1004.
51. Sabat R, Wallace E, Endesfelder S, Wolk K: IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets 2007;11:601-612.
52. Wei CC, Hsu YH, Li HH, Wang YC, Hsieh MY, Chen WY, Hsing CH, Chang MS: IL-20: biological functions and clinical implications. J Biomed Sci 2006;13:601-612.
53. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, Bernard FX, Nau F, Guillet G, Dagregorio G, Yssel H, Lecron JC, Morel F: A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007;150:407-415.
54. Livden JK, Nilsen R, Bjerke JR, Matre R: In situ localization of interferons in psoriatic lesions. Arch Dermatol Res 1989;28:392-397.
55. McKenzie RC, Sabin E, Szepietowski JC, Gracie JA, Forsey RJ, Howie S: Interferon gamma in keratinocytes in psoriasis. Eur J Dermatol 2003;13:315-316.
56. Higashiyama M, Hashimoto K, Matsumoto K, Yoshikawa K: Differential expression of transforming growth factor-alpha (TGF-alpha) and EGF receptor in transitional area of psoriatic epidermis. J Dermatol Sci 1994;7:45-53.
57. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M: The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998;139:390-395.
58. Doger FK, Dikicioglu E, Ergin F, Unal E, Sendur N, Uslu M: Nature of cell kinetics in psoriatic epidermis. J Cutan Pathol 2007;34:257-263.
59. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-1146.
60. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS: Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003;102:161-168.